What is Denali Therapeutics Inc.'s other accrued liabilities?

Denali Therapeutics Inc. (DNLI) reported other accrued liabilities of $5.08M in Q1 2026.

Denali Therapeutics Inc. DNLI Other accrued liabilities

Other accrued liabilities at other companies

Viking TherapeuticsVKTX

——

BridgeBio PharmaBBIO

——

Praxis Precision Medicines, Inc.PRAX

——

Other financials

Income statement

See full

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

See full

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

See full

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

See full

Market cap$3.93B+54.2%

Profitability

See full

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

See full

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Denali Therapeutics Inc.'s other accrued liabilities?: Denali Therapeutics Inc. (DNLI) reported other accrued liabilities of $5.08M in Q1 2026.